Investigating how cancer immunotherapy can trigger immune responses in lung cancer

Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLC

NIH-funded research University of Maryland Baltimore · NIH-11001496

This study is exploring how treating one tumor can sometimes help fight other tumors in people with non-small cell lung cancer, and it's designed for patients looking for better treatment options that combine immunotherapy and radiation.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Maryland Baltimore NIH-funded
Lab location1 site (Baltimore, United States)
Project IDNIH-11001496 on NIH RePORTER

What this research studies

This research focuses on understanding the abscopal effect, where localized cancer treatment can lead to systemic anti-tumor responses in non-small cell lung cancer (NSCLC). By using advanced techniques like tumor barcoding and high-throughput sequencing, the study aims to create genetically engineered mouse models that can accurately predict how different treatments work together. This approach seeks to improve the effectiveness of immunotherapy combined with radiation therapy, particularly for patients whose tumors do not respond well to current treatments.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have not responded to standard immunotherapy treatments.

Not a fit: Patients with other types of lung cancer or those who have not been diagnosed with cancer may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with non-small cell lung cancer, potentially improving their outcomes.

How similar studies have performed: Previous research has shown promise in using similar immunotherapy approaches, but this specific combination and methodology is relatively novel.

Where this research is happening

Baltimore, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.